The UK and US have reached a landmark commercial pact that will maintain zero import taxes on British drug exports entering the American market.
Agreement Details of the Deal
Under the terms of the agreement, the UK has agreed to boost expenditure on medicines through the public health system. This pledge guarantees that duties on these vital goods will be held at zero for a timeframe of the next three years.
This agreement comes after earlier warnings to hike tariffs on patented pharmaceutical products, with potential rates discussed as high as 100%.
"This deal with the United Kingdom reinforces the international landscape for new treatments and introduces long-overdue fairness to transatlantic drug exports," a statement said.
Commercial Significance
Pharmaceuticals are one of the Britain's largest export categories to the America, which is by far the largest buyer for large UK drugmakers.
Trade data indicate that in the 12 months prior to last September, the UK sold pharmaceutical products valued at billions to the US. This amount accounted for 17.4% of British export trade in that span.
"This agreement protects jobs, stimulates capital expenditure and paves the way for the UK to emerge as a worldwide center for biotech and pharma," a minister remarked.
Detailed NHS Changes
The pact entails several notable commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it considers new medicines to be too expensive by 25%.
- Increased NHS Spending: There is a goal to raise overall NHS spending on treatments from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The amount pharmaceutical firms must pay back to the NHS to control costs will be limited at fifteen percent. Previously, rebates exceeded 20%.
Broader Context
This agreement follows a long-running tension between the sector and the UK government over drug pricing and NHS adoption.
These tensions were heightened by claims that US patients were paying several times more for the same drugs than people in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while multi-billion-dollar expansions have been directed toward projects in the United States.
A senior figure acknowledged that the NHS must spend more on medicines, noting that its spending on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
